Evli Corporate Finance acted as an exclusive advisor to the owners of Mabtech in the sales process to IK Investment Partners, with Merieux Equity Partners acquiring a minority stake. The founders and the management team will continue to be invested.
Founded in 1986 by scientists at the Department of Immunology, Stockholm University, Mabtech has become a world leading niche player in immune monitoring with an outstanding product portfolio of high-quality monoclonal antibodies, kits, and instruments for analyses of immune responses and the immune system. The Company is built by researchers, for researchers, and offers a customer-friendly approach, technology leadership, proprietary methods, and innovation. With its strong value proposition, Mabtech has become a well-reputable brand among researchers and companies worldwide to study immune responses in e.g. cancer, allergy, infectious diseases, as well as to monitor vaccine trials.
Evli Corporate Finance continues to cement its strong position in the Nordic healthcare sector with over 10 transactions during the last five years, with a total value exceeding EUR 500 million.
For more information, please contact:
Henrik Westling, tel. +46 73 069 8049, henrik.westling@evli.com
Victor Widerberg, tel. +46 70 565 1680, victor.widerberg@evli.com
Edwin Olsson, tel. +46 73 050 4157, edwin.olsson@evli.com
